Deepika G1, Gokul S1, Meghana Vadlamudi1, Punnagai K2, Raja N3, Sabitha Panchagiri1,*
1Department of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, SRIHER (DU), Chennai, Tamil Nadu, INDIA.
2Department of Phamacology, Sri Ramachandra Medical and Research Centre, SRIHER (DU), Chennai, Tamil Nadu, INDIA.
3Department of Pharmaceutics, B.S. Abdur Rahman Crescent Institute of Science & Technology (DU), Vandalur, Tamil Nadu, INDIA.
Correspondence: Dr. Sabitha Panchagiri
Associate Professor, Department of Pharmacy Practice, Sri Ramachnadra Faculty of Pharmacy SRIHER, Porur, Chennai, Tamil Nadu – 600116. INDIA.
Email : sabithap@sriramachandra.edu.in
ABSTRACT
Background : Huge efforts have been made for vaccine research and administration in light of the public health measures implemented for the COVID-19 pandemic. Safety information following vaccination is not available due to the vaccine’s recent development within in shorter duration. To allay concerns about adverse effects from vaccination, evidenced based information on immunisation must be continuously added. Methods : This cross sectional study was carried out in COVID-19 vaccine beneficiaries (Covishield, Covaxin, Sputnik-V) received two doses at Sri Ramachandra Hospital, Porur, Chennai, between September 2021 to March 2022. Relevant data was collected in a structured data collection form through telephonic interview. Results were retrieved and analysed. A simple descriptive statistical analysis was used to draw the results and expressed in percentage. Results: A total of 751 participants responded to the interview out of 803. Among them 127 (52%), 244 (70%) and 97 (60%) for Sputnik-V, Covishield and Covaxin. 468 (62.3%; range 18-60 years) observed with at least one adverse effect. 82.3% (n=385) of respondents reported very common adverse events, followed by 13.5% (n=63) common, 3.8% (n=18) uncommon, and 0.4% (n=2) unusual adverse events following immunization was observed and last for less than 72 hours. 70.5% used medication to treat AEFI. Conclusion: No severe or fatal adverse events were observed which lead to hospitalization hence all the 3 vaccines are safe. This study helps to build trust and confidence among the eligible beneficiaries so as to extend the benefits of vaccinations to control the current pandemic situation.
Keywords: Vaccine beneficiaries, Covishield, Covaxin, Sputnik–V